Effect of Fedratinib Versus Best Available Therapy on Patient-Reported Outcomes in Patients with Myelofibrosis Who Were Previously Treated with Ruxolitinib: Results from the Phase 3 FREEDOM2 Trial

被引：0
|
作者：
Harrison, Claire [1 ]
Lord-Bessen, Jennifer [2 ]
Shi, Ling [3 ]
Guo, Shien [3 ]
Yucel, Aylin [2 ]
Zissler, Dorothy [2 ]
Jones, Shalon [2 ]
Slaff, Samantha [2 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, London, England
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Evidera, Bethesda, MD USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198368
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6624 / 6625
页数：2
相关论文
共 50 条
  • [1] A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)
    Vianelli, Nicola
    Benevolo, Giulia
    Vannucchi, Alessandro
    Harrison, Claire N.
    Loschi, Michael
    Al-Ali, Haifa Kathrin
    Bonifacio, Massimiliano
    Cervantes, Francisco
    Wrobel, Tomasz
    Barosi, Giovanni
    Kiladjian, Jean-Jaques
    Verstovsek, Srdan
    Mesa, Ruben A.
    Rose, Shelonitda
    Gharpure, Vishwanath
    Hernandez, Christopher
    Zhang, Jun
    Passamonti, Francesco
    BLOOD, 2021, 138
  • [2] Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study
    Harrison, Claire N.
    Mesa, Ruben
    Talpaz, Moshe
    Al-Ali, Haifa Kathrin
    Xicoy, Blanca
    Passamonti, Francesco
    Palandri, Francesca
    Benevolo, Giulia
    Vannucchi, Alessandro M.
    Mediavilla, Clemence
    Iurlo, Alessandra
    Kim, InHo
    Brown, Patrick
    Hernandez, Christopher
    Rose, Shelonitda
    Wang, Jia
    Kiladjian, Jean-Jacques
    BLOOD, 2023, 142
  • [3] Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3trial
    Harrison, Claire N.
    Mesa, Ruben
    Talpaz, Moshe
    Al-Ali, Haifa Kathrin
    Xicoy, Blanca
    Passamonti, Francesco
    Palandri, Francesca
    Benevolo, Giulia
    Vannucchi, Alessandro Maria
    Mediavilla, Clemence
    Iurlo, Alessandra
    Kim, Inho
    Rose, Shelonitda
    Brown, Patrick
    Hernandez, Christopher
    Wang, Jia
    Kiladjian, Jean-Jacques
    LANCET HAEMATOLOGY, 2024, 11 (10): : e729 - e740
  • [4] PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY
    Verstovsek, S.
    Vannucchi, A. M.
    Platzbecker, U.
    Cervantes, F.
    Gupta, V.
    Lavie, D.
    Passamonti, F.
    Winton, E. F.
    Dong, H.
    Kawashima, J.
    Maltzman, J. D.
    Kiladjian, J-J.
    Harrison, C. N.
    HAEMATOLOGICA, 2017, 102 : 320 - 321
  • [5] Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
    Harrison, Claire N.
    Vannucchi, Alessandro M.
    Platzbecker, Uwe
    Cervantes, Francisco
    Gupta, Vikas
    Lavie, David
    Passamonti, Francesco
    Winton, Elliott F.
    Dong, Hua
    Kawashima, Jun
    Maltzman, Julia D.
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    LANCET HAEMATOLOGY, 2018, 5 (02): : E73 - E81
  • [6] Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
    Harrison, Claire N.
    Schaap, Nicolaas
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Jourdan, Eric
    Silver, Richard T.
    Schouten, Harry C.
    Passamonti, Francesco
    Zweegman, Sonja
    Talpaz, Moshe
    Verstovsek, Srdan
    Tang, Derek
    Abraham, Pranav
    Lord-Bessen, Jennifer
    Rose, Shelonitda
    Guo, Shien
    Liao, Weiqin
    Mesa, Ruben A.
    HEMASPHERE, 2021, 5 (05):
  • [7] Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).
    Harrison, Claire N.
    Vannucchi, Alessandro M.
    Platzbecker, Uwe
    Cervantes, Francisco
    Gupta, Vikas
    Lavie, David
    Passamonti, Francesco
    Winton, Elliott F.
    Dong, Hua
    Kawashima, Jun
    Maltzman, Julia D.
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediateor high-risk myelofibrosis previously treated with ruxolitinib
    Harrison, Claire
    Gupta, Vikas
    Yacoub, Abdulraheem
    Fazal, Salman
    Miller, Carole
    Verstovsek, Srdan
    Mesa, Ruben
    Barosi, Giovanni
    Kiladjian, Jean-Jacques
    Mattison, Ryan
    Rein, Lindsay
    Reeves, Brandi
    Oh, Stephen
    Parameswaran, Vinod
    Deeg, H. Joachim
    Rose, Shelonitda
    Chia, Vincent
    Wang, Tianhua
    Talpaz, Moshe
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 110 - 111
  • [9] Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib
    Gupta, Vikas
    Yacoub, Abdulraheem
    Fazal, Salman
    Miller, Carole
    Verstovsek, Srdan
    Mesa, Ruben
    Harrison, Claire
    Barosi, Giovanni
    Kiladjian, Jean-Jacques
    Mattison, Ryan
    Rein, Lindsay
    Reeves, Brandi
    Oh, Stephen
    Parameswaran, Vinod
    Deeg, Joachim
    Rose, Shelonitda
    Chia, Vincent
    Wang, Tianhua
    Talpaz, Moshe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S331 - S332
  • [10] Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
    Strand, Vibeke
    Alemao, Evo
    Lehman, Thomas
    Johnsen, Alyssa
    Banerjee, Subhashis
    Ahmad, Harris A.
    Mease, Philip J.
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
12345